AMENDMENT NO. 1 TO SALES AGREEMENTSales Agreement • February 27th, 2019 • Aduro Biotech, Inc. • Pharmaceutical preparations • New York
Aduro Biotech, Inc. (the “Company”), and Cowen and Company, LLC (“Cowen”), are parties to that certain Sales Agreement dated August 2, 2017 (the “Original Agreement”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Original Agreement. The parties, intending to be legally bound, hereby amend the Original Agreement as follows:
RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN ADURO BIOTECH, INC. and ELI LILLY AND COMPANY December 18, 2018Research Collaboration and Exclusive License Agreement • February 27th, 2019 • Aduro Biotech, Inc. • Pharmaceutical preparations
This RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of December 18, 2018 (the “Effective Date”) by and between Aduro Biotech, Inc., a Delaware corporation having a place of business at 740 Heinz Avenue, Berkeley, California 94710 (“Aduro”), and Eli Lilly and Company, an Indiana corporation having a place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Each of Aduro and Lilly is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
